Earnings
Sanofi Plans Late-Stage Deals To Offset Dupixent's Patent Expiry, With A Strategy Update Due Before Year-End
Management wants late-stage and commercial drugs, and the CFO would not put a number on deal capacity.
Sanofi (SNY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Management wants late-stage and commercial drugs, and the CFO would not put a number on deal capacity.
Earnings
The drugmaker now sees low-teens sales growth and mid-teens business EPS growth at constant rates, with third-quarter business EPS at €3.55.